|Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.|
|Jump to Full Text|
|PMID: 19799786 Owner: NLM Status: MEDLINE|
|INTRODUCTION: Systemic sclerosis (SSc) (scleroderma) is a complex autoimmune disease that clinically manifests as progressive fibrosis of the skin and internal organs. Anti-centromere antibodies (ACAs), anti-topoisomerase antibodies (ATAs), and anti-RNA polymerase III antibodies (ARAs) are three mutually exclusive SSc-associated autoantibodies that correlate with distinct clinical subsets characterized by extent of cutaneous involvement and pattern of organ involvement. The current report sought to determine whether plasma cytokine profiles differ in SSc patients grouped according to these SSc-associated autoantibody subsets.
METHODS: Plasma from 444 SSc patients and 216 healthy controls was obtained from the Scleroderma Family Registry and University of Texas Rheumatology Division. Patients were classified according to the presence of ACAs, ATAs, ARAs, or none of the above (antibody-negative). Levels of 13 cytokines were determined using multiplex assays.
RESULTS: Compared with females, healthy control males had higher plasma levels of IL-2 (P = 0.008), IL-5 (P = 0.01) and IL-8 (P = 0.01). In addition, in controls, IL-6 (P = 0.02) and IL-17 (P = 0.01) levels increased with advancing age. After adjusting for age and gender, SSc patients had higher circulating levels of TNFalpha (P < 0.0001), IL-6 (P < 0.0001), and IFNgamma (P = 0.05) and lower IL-17 (P = 0.0005) and IL-23 (P = 0.014). Additional analyses demonstrated that disease duration also influenced these cytokine profiles. IL-6 was elevated in ATA-positive and ARA-positive patients, but not in ACA-positive patients. IL-8 was uniquely increased in the ATA-positive subset while both ATA-positive and ACA-positive subsets had elevated IFNgamma and IL-10. IL-5 was only significantly increased in the ACA-positive subset. Lastly, patients with interstitial lung disease had elevated IL-6 and patients with pulmonary hypertension had elevated IL-6 and IL-13.
CONCLUSIONS: Plasma cytokine profiles differ in SSc patients based on the presence of SSc-associated autoantibodies. Plasma cytokine profiles in SSc patients may also be affected by disease duration and the pattern of internal organ involvement.
|Pravitt Gourh; Frank C Arnett; Shervin Assassi; Filemon K Tan; Mei Huang; Laura Diekman; Maureen D Mayes; John D Reveille; Sandeep K Agarwal|
Related Documents :
|16422126 - Association of impaired glucose tolerance with increased heart rate and subclinical inf...
15126536 - Increased c-reactive protein levels in the polycystic ovary syndrome: a marker of cardi...
15900566 - Usefulness of high-sensitivity il-6 measurement for clinical characterization of patien...
18285696 - Interleukin-6 is a better predictor of mortality as compared to c-reactive protein, hom...
18079146 - Kidney transplantation in the elderly--the norwegian experience.
11154806 - Relative sparing of the parietal cortex in cerebellar ataxia documented by positron emi...
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2009-10-02|
|Title: Arthritis research & therapy Volume: 11 ISSN: 1478-6362 ISO Abbreviation: Arthritis Res. Ther. Publication Date: 2009|
|Created Date: 2009-11-27 Completed Date: 2010-02-03 Revised Date: 2012-06-12|
Medline Journal Info:
|Nlm Unique ID: 101154438 Medline TA: Arthritis Res Ther Country: England|
|Languages: eng Pagination: R147 Citation Subset: IM|
|Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas Health Science Center at Houston, 6431 Fannin M.S.B. 5.278, Houston, TX 77030, USA. Pravitt.Gourh@uth.tmc.edu|
|APA/MLA Format Download EndNote Download BibTex|
Cytokines / blood*
Enzyme-Linked Immunosorbent Assay
Scleroderma, Systemic / blood*, immunology*
|3UL1RR024148/RR/NCRR NIH HHS; K08 AR054404/AR/NIAMS NIH HHS; K08 AR054404-01A2/AR/NIAMS NIH HHS; K08 AR054404-02/AR/NIAMS NIH HHS; K08 AR054404-04/AR/NIAMS NIH HHS; K08AR054404/AR/NIAMS NIH HHS; N01-AR-0-2251/AR/NIAMS NIH HHS; P50 AR054144-045280/AR/NIAMS NIH HHS; P50AR054144/AR/NIAMS NIH HHS|
Journal ID (nlm-ta): Arthritis Res Ther
Publisher: BioMed Central
Copyright ©2009 Gourh et al.; licensee BioMed Central Ltd.
Received Day: 8 Month: 6 Year: 2009
Revision Requested Day: 7 Month: 7 Year: 2009
Revision Received Day: 19 Month: 8 Year: 2009
Accepted Day: 2 Month: 10 Year: 2009
Print publication date: Year: 2009
Electronic publication date: Day: 2 Month: 10 Year: 2009
Volume: 11 Issue: 5
First Page: R147 Last Page: R147
Publisher Id: ar2821
PubMed Id: 19799786
|Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations|
|Pravitt Gourh1||Email: Pravitt.Gourh@uth.tmc.edu|
|Frank C Arnett1||Email: Frank.C.Arnett@uth.tmc.edu|
|Shervin Assassi1||Email: Shervin.Assassi@uth.tmc.edu|
|Filemon K Tan1||Email: Filemon.K.Tan@uth.tmc.edu|
|Mei Huang1||Email: Mei.Huang@uth.tmc.edu|
|Laura Diekman1||Email: Laura.Diekman@ut.tmc.edu|
|Maureen D Mayes1||Email: Maureen.D.Mayes@uth.tmc.edu|
|John D Reveille1||Email: John.D.Reveille@uth.tmc.edu|
|Sandeep K Agarwal1||Email: Sandeep.K.Agarwal@uth.tmc.edu|
1Division of Rheumatology and Clinical Immunogenetics, Department of Internal Medicine, University of Texas Health Science Center at Houston, 6431 Fannin M.S.B. 5.278, Houston, TX 77030, USA
Systemic sclerosis (SSc) (scleroderma) is a chronic, multisystem autoimmune disease clinically characterized by progressive fibrosis of the skin and internal organs. Pathologically, SSc exhibits three cardinal features: inflammation and autoimmunity, vasculopathy, and excessive extracellular matrix production and deposition. How the disease process is triggered remains to be established, but current paradigms point towards immune dysregulation as a central process in the pathogenesis of SSc.
Multiple lines of evidence support the importance of immune dysregulation in the pathogenesis of SSc. Skin biopsies of early scleroderma skin demonstrate perivascular infiltrates of mononuclear inflammatory cells, including CD4+ T cells, which produce cytokines and chemokines that induce tissue damage, recruit additional inflammatory cells, and promote extracellular matrix production and fibrosis . Whole genome gene expression profiling of peripheral blood has demonstrated the presence of a type-I interferon signature in SSc . There have been conflicting reports in the literature regarding the role of T cells and the T-helper type 1 (Th1)/T-helper type 2 (Th2) cytokine balance in SSc. Some studies support Th1 activation in the peripheral blood with production of IFNγ, while others predict a preferential involvement of Th2 cells in SSc with increased levels of IL-4 and IL-13 [3-5]. Lastly, several reports have demonstrated increased circulating levels of cytokines in plasma of patients with SSc compared with controls with conflicting results [4,6-11]. These conflicting results may be due to the samples being collected in different stages of the disease process. Alternatively, these conflicting results could reflect the heterogeneity amongst SSc patients.
The presence of multiple SSc-associated autoantibodies has been well described [12-15]. Interestingly, the SSc-associated autoantibodies correlate with distinct clinical subsets characterized by the extent of cutaneous involvement and the pattern of organ involvement . For example, pulmonary arterial hypertension is more common in patients with anti-centromere antibodies (ACAs), pulmonary fibrosis is more common in patients with anti-topoisomerase antibodies (ATAs), and scleroderma renal crisis is more common in patients with anti-RNA polymerase III antibodies (ARAs) . Whether the clinical differences observed in these autoantibody subsets also reflect differences in immune dysregulation is not known.
In the current report, a comprehensive panel of cytokines was assessed in a large cohort of SSc patients and controls to determine whether SSc patient have differences in plasma cytokines and whether these profiles correlate with autoantibody subsets of SSc.
Patients and unrelated controls were selected from the Scleroderma Family Registry and DNA Repository and University of Texas Rheumatology Division, dating from 1986 to present . All SSc patients fulfilled American College of Rheumatology preliminary criteria for disease classification  or had at least three of the five features of CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasias). All SSc patients were classified based on the presence of scleroderma-associated autoantibodies including ACAs, ATAs, and ARAs or the absence of these three antibodies (Ab-Neg). SSc patients negative for antinuclear antibodies were excluded from this study. From these groups, a total of 444 SSc patients were randomly chosen from a cohort of 665 SSc patients. Two hundred and sixteen healthy controls were also randomly selected. Samples used in the study were obtained at the earliest time point available.
The patients were classified as having limited or diffuse cutaneous SSc according to published criteria . SSc-associated pulmonary fibrosis was defined as the presence of typical findings on chest high-resolution computerized tomography, regular chest computerized tomography or radiograph, or a restrictive pattern on pulmonary function testing. Pulmonary hypertension was defined as estimated peak right ventricular systolic pressure ≥ 40 mmHg on echocardiography or pulmonary arterial systolic pressure ≥ 40 mmHg by right heart catheterization. Scleroderma renal crisis was characterized by the presence of new-onset accelerated systemic hypertension with evidence of renal impairment. Myositis was defined as inflammatory myositis referenced in the patient's chart or as objective muscle weakness and elevated creatine kinase levels.
All study subjects provided written informed consent and the study was approved by the institutional review board of the University of Texas Health Science Center at Houston.
Sera were tested for antinuclear antibodies using indirect immunofluorescence with HEp-2 cells as the antigen substrate (Antibodies Inc., Davis, CA, USA). ACAs were determined by their distinctive indirect immunofluorescence pattern on HEp-2 cells. Autoantibodies to topoisomerase I were determined by passive immunodiffusion against calf thymus extract (Inova Diagnostics, San Diego, CA, USA). ARAs were determined by enzyme-linked immunoassay (MBL Co. Ltd, Nagoya, Japan) using a cutoff value defined as 2.5 standard deviations above the mean of 40 controls.
Plasma was collected in ethylenediamine tetraacetic acid blood collection tubes and stored at -80°C for bulk analysis. Cytokine ELISAs were performed using electrochemiluminescent multiplex assays (Meso Scale Discovery, Gaithersburg, MD, USA) to determine the plasma levels of 13 cytokines (IFNγ, TNFα, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17 and IL-23) . Calibration curves were prepared in the supplied assay diluents for human serum, with a range of 2,500 to 1.2 pg/ml. Cytokine concentrations were determined with MSD Workbench 3.0 software (Meso Scale Discovery, Gaithersburg, MD, USA), using curve fit models (log- log or four-parameter log-logistic).
Statistical analyses were performed using SAS 9.1.3 software (SAS Institute Inc., Cary, NC, USA). Cytokine data were log-transformed due to the non-normal distribution of plasma cytokines in both the healthy controls and the SSc population . The cytokine values were compared between two groups using an unpaired Student's t test. Logistic regression analysis was used to compare plasma cytokine levels when controlling for age and gender. Association of plasma cytokines with clinical manifestations of SSc was performed using logistic regression with adjustment for age and gender.
The cohort consisted of 216 healthy controls and 444 scleroderma patients of similar ages (Table 1). Of the scleroderma patients, 241 patients had limited SSc and 200 patients had diffuse SSc. All patients were antinuclear antibody-positive, and SSc-associated antibodies were present in 330 patients: 109 patients with ACAs, 112 patients with ATAs, and 109 patients with ARAs. One hundred and fourteen patients were negative for all three SSc-associated antibodies (Ab-Neg). Furthermore, no patients had more than one of the above SSc-associated antibodies present.
The mean disease duration for all SSc patients was 6.9 years from the time of first non-Raynaud's phenomenon manifestation. ACA-positive patients had the longest disease duration, with a mean duration of 9.3 years. ATA-positive patients had a mean disease duration of 8.0 years, and ARA-positive patients and Ab-Neg patients had disease durations of 5.4 years and 4.9 years, respectively. The differences in disease duration in patients grouped according to SSc-associated antibodies were statistically significant (P < 0.0001 by analysis of variance).
To determine whether plasma cytokines levels were affected by age and gender, plasma cytokine levels were determined on plasma from 216 healthy controls. Plasma cytokine levels were not normally distributed across the cohort of healthy controls, so the data were logn-transformed .
Compared with females (n = 99), male healthy controls (n = 117) had higher circulating levels of IL-2 (P = 0.008), IL-5 (P = 0.01) and IL-8 (P = 0.01) (Figure 1). In contrast, male controls had lower circulating levels of IL-13 (P = 0.03) and IL-23 (P = 0.006). Male controls tended to have increased circulating levels of IL-1β, IL-4 and IL-10 (P < 0.10) but no significant differences were observed in circulating levels of TNFα, IFNγ, IL-6, IL-12p70, and IL-17.
To determine whether increasing age alters the circulating plasma cytokine levels, healthy controls were grouped according to age in 20-year intervals. As seen in Figure 2, IL-6 (P = 0.02) and IL-17 (P = 0.01) levels increased with advancing age. There was also a trend for increasing levels of IL-8 with age (P = 0.07). No changes were noted in IL-1β, IL-2, IL-4, IL-5, IL-10, IL-12p70, IL-13, IL-23, IFNγ, and TNFα.
Together these data demonstrate that circulating cytokine levels are different in healthy males and females and are dependent on age.
Circulating cytokine levels were determined in plasma from SSc patients and were compared with those for control patients (Table 2). Compared with healthy control subjects, SSc patients had higher circulating levels of TNFα (P < 0.0001), IL-6 (P < 0.0001) and IL-13 (P = 0.05) but lower circulating levels of IL-17 (P = 0.0009) and IL-23 (P = 0.04). No differences were observed in circulating levels of IL-1β, IL-2, IL-4, IL-5, IL8, IL-10, and IFNγ.
Given the observation that age and gender can influence plasma cytokine levels in healthy controls, comparisons between scleroderma patients and healthy controls were performed adjusting for age and gender using logistic regression analysis (Table 2). After adjusting for age and gender, patients with SSc had higher circulating levels of TNFα and IL-6 and lower circulating levels of IL-17 and IL-23. In addition, SSc patients had higher circulating levels of IFNγ; however, the previous unadjusted change in plasma IL-13 was no longer significant.
Together these data demonstrate that SSc patients have an increase in circulating levels of TNFα, IL-6, and IFNγ and a decrease in IL-17 and IL-23.
Immune dysregulation is commonly thought to be important in the early pathogenesis of SSc. Whether the cytokine alterations that might be observed early in the disease process persist as the disease progresses, however, is unclear. To determine whether disease duration influenced the patterns of plasma cytokine profiles, patients were grouped according to disease duration: 0 to 5 years (n = 196 patients), 5 to 10 years (n = 107 patients), and >10 years (n = 94 patients). The disease duration was not known for 47 SSc patients, and these patients were excluded from this analysis.
TNFα and IL-6 were significantly increased in SSc patients with a disease duration of 0 to 5 years (P < 0.0001 and P < 0.0001, respectively) and a duration of 5 to 10 years (P < 0.0001 and P = 0.007, respectively) compared with controls (Figure 3). TNFα and IL-6 levels were similar between controls and SSc patients with disease duration >10 years. Alterations in circulating levels of other cytokines became apparent after controlling for disease duration as well as age and gender. For example, circulating levels of IL-5, IL-10 and IFNγ were only elevated in patients with disease duration >10 years compared with healthy controls (P = 0.04, P = 0.008, and P = 0.03, respectively). In contrast, IL-13 was slightly increased in patients with disease duration <5 years (P = 0.03). Lastly, IL-17 levels remained decreased in patients independent of disease duration, but IL-23 levels were only decreased in SSc patients with disease duration of 0 to 5 years or 5 to 10 years compared with controls.
These data suggest that the circulating cytokine profiles are different in patients based on disease duration, and suggest that alterations in immune balance may change during different stages of SSc.
The presence of scleroderma-associated autoantibodies is associated with distinct clinical phenotypes of SSc ; however, it is not known whether these different subsets have different alterations in immune function. Comparisons of plasma cytokines were performed in each group based on the presence of scleroderma-associated autoantibodies (ACAs, ATAs, ARAs, Ab-Neg), controlling for age and gender using logistic regression analysis.
As seen in Figures 4 and 5, all four groups of SSc patients had a significant increase in TNFα and a decrease in IL-23. The ATA-positive, ARA-positive and Ab-Neg subsets had a statistically significant increase in IL-6, which was not observed in the ACA-positive group. Furthermore, IL-17 was significantly decreased in all groups compared with controls, except in the Ab-Neg group. IL-8 was uniquely increased in the ATA-positive subset. Interestingly, both ATA-positive and ACA-positive subsets had an increase in IFNγ and IL-10, but IL-5 was only significantly increased in the ACA-positive subset. Lastly, the ARA-positive and Ab-Neg group did not have alterations in circulating IFNγ, IL-8 or IL-10.
Together these data suggest that the presence of SSc-associated autoantibodies may identify patients with different patterns of circulating cytokines and that different pathways of immune dysregulation may underlie the development of SSc.
To determine whether circulating plasma cytokine profiles were associated with clinical involvement in SSc, plasma cytokines in patients with and without interstitial lung disease, pulmonary hypertension, SSc renal crisis, Sjogren's syndrome/sicca symptoms, myositis or primary biliary cirrhosis were compared with controls, using logistic regression to control for age and gender (Table 3). Patients were excluded from this analysis if the specific status was not known.
Patients with higher circulating IL-6 were more likely to have interstitial lung disease (odds ratio = 1.33, 95% confidence interval = 1.08 to 1.62). Patients with pulmonary hypertension were more likely to have higher IL-6 (odds ratio = 1.31, 95% confidence interval = 1.04 to 1.67) and IL-13 (odds ratio = 1.42, 95% confidence interval = 1.04 to 1.94). Patients with SSc renal crisis were more likely to have elevated TNFα levels (odds ratio = 2.22, 95% confidence interval = 1.11 to 4.45). Interestingly, patients with Sjogren's syndrome/sicca symptoms were more likely to have lower IL-8 (odds ratio = 0.89, 95% confidence interval = 0.81 to 0.99) and IL-1β (odds ratio = 0.75, 95% confidence interval = 0.63 to 0.88).
Finally, we performed a logistic regression analysis using the individual components of the Medsger Damage Index (general, peripheral vascular, skin score, joint/tendon, muscle, gastrointestinal tract, and heart) as a continuous variable. Interestingly, IL-6 was associated with total skin scores (regression coefficient = 0.77; 95% confidence interval = 0.05 to 1.49) and IL-17 levels were associated with joint/tendon scores (regression coefficient = 0.27; 95% confidence interval = 0.10 to 0.43).
Together these data demonstrate that there are distinct differences in the plasma cytokine profiles in patients representing different clinical manifestations of SSc.
In the current report, the circulating plasma cytokine profile was determined in patients with SSc compared with controls using a large cross-sectional cohort of SSc patients and healthy controls. We observed that SSc patients have higher levels of TNFα, IL-6 and IFNγ, but lower levels of IL-17 and IL-23. We also observe that the disease duration and the presence of SSc autoantibodies have an influence on these cytokine profiles. Lastly, it was discerned that specific clinical manifestations of SSc, such as interstitial lung disease, pulmonary hypertension or SSc renal crisis, are also associated with alterations in distinct plasma cytokine levels.
Collectively, these data bring to light the complex immunopathogenesis of SSc and echo the clinical heterogeneity that is seen within SSc. The SSc-associated autoantibodies are clinically useful to risk-stratify patients for the systemic involvement of SSc. Accordingly, we observe that there are also differences in circulating cytokine levels when using these autoantibodies to classify SSc patients. For example, ATA-positive patients are the only subset with an increase in IL-8. ATA-positive and ACA-positive patients both have an increase in IFNγ and IL-10, while only ACA-positive patients present an increase in IL-5. Based on the current data, the ARA-positive subset appears to be a distinct subset. Similar to ATAs and ACAs, ARAs show an increase in TNFα and IL-6 as well as a decrease in IL-17 and IL-23. The ARA-positive subset, however, does not have alterations in the Th1/Th2 cytokines that are observed in the ATA-positive subset or the ACA-positive subset.
Alterations in plasma cytokine levels, including IL-6, TNFα, IL-10 and IL-4, have been reported by several groups in the past, with varying results [6-10]. The differences are probably due to the heterogeneity within SSc, differences in disease duration, differences in gender, disease activity, and small sample size of these studies. The current report utilizes the largest cohort of SSc patients and healthy controls to date. This enables controlling for variables such as gender and age, which we have shown can influence circulating cytokine levels even in healthy controls as well as in SSc patients. Similar to previous reports, we demonstrate an increase in circulating levels of IL-6 [6,7]. Interestingly, these changes appear to be less significant in patients with longer disease duration, although we cannot rule out a contribution of disease activity. IL-6 is a pleiomorphic cytokine produced by T cells, B cells, monocytes, endothelial cells, and fibroblasts, and is involved in regulating many cellular processes including multilineage blast cell colony formation, T-cell differentiation and fibroblast behavior . IL-6 is therefore probably a key cytokine in the immunopathogenesis of SSc.
Scleroderma has often been considered a Th2 cytokine disease [3,23]. Th1 cytokines such as IFNγ have antifibrotic effects, while Th2 cytokines such as IL-4 and IL-13 have profibrotic effects . Indeed, Th2 cells have been cloned from SSc skin with greater frequency than Th1 cells, although not exclusively . Other reports have not, however, consistently demonstrated a Th2 cytokine profile in SSc patients [11,25,26]. In the current report, the ATA-positive and ACA-positive subsets have an increase in the Th1 cytokine IFNγ. Both subsets present an increase in the Th2 cytokine IL-5, but it is only statistically significant in the ACA-positive subset. These data do not point to a selective increase in Th2 cytokines. Additional studies using more sensitive measures of the Th1/Th2 cytokine balance are needed to better address this aspect.
T-helper type 17 cells have recently been implicated as key T cells in the pathogenesis of autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis and ankylosing spondylitis [27-29]. IL-17 and IL-23 have been reported to be increased in the plasma of patients in two small Japanese cohorts of SSc patients [30,31]. In the current large cohort, when controlling for age, gender, and autoantibody status, we observed a decrease in circulating IL-17 and IL-23, especially in patients with shorter disease duration. We cannot definitively explain these differences but possible explanations are the sample sizes of the cohorts and the differences in genetic background of Japanese versus the current cohort of North American Caucasians, which may influence the cytokine profile. Given the potential importance of the T-helper type 17 pathway in autoimmune diseases, future efforts should focus on delineating the role of T-helper type 17 cells in SSc immunopathogenesis.
A final observation of potential interest is the association of circulating cytokines with systemic manifestations of SSc. Similar to prior reports, we observed an association of IL-6 with interstitial lung disease . We also noted that IL-6 and IL-13 levels were increased in patients with pulmonary hypertension, and that TNFα levels were associated with the presence of renal crisis. While alterations in cytokine levels were associated with clinical manifestations of SSc, prospective studies are needed to determine whether measuring these cytokine levels in patients would be helpful in predicting the development of these detrimental clinical manifestations.
The current report has several limitations that should be acknowledged. While the plasma samples were obtained from a large cohort of SSc patients and healthy controls, accurate data for immunosuppressive medications were not available at the time of the present publication. Another limitation is the cross-sectional design of the current study. The data reported herein identify disease duration as a factor that influences cytokine profiles. This might be particularly relevant with regards to the ACA-positive group, which has longer disease duration than the other autoantibody groups. A prospective study with sequential plasma samples would be beneficial to better understand the immune changes that are associated with the development of SSc as well as the progression of the disease and disease activity. It should also be noted that the SSc-associated autoantibody group (Ab-Neg) remains a heterogeneous group of patients - as defined by the presence of other autoantibodies such as anti-fibrillarin, anti-PM-Scl or anti-Th/To  - and whether these less common subsets also have differences in the plasma cytokine profiles remains to be determined.
SSc is associated with alterations in circulating plasma cytokines. These alterations are influenced by gender, age, disease duration and the presence of specific SSc-associated autoantibodies. These results highlight the complex immunopathogenesis of SSc and point to several potential targets that could be considered for monitoring disease progression and treatment of SSc.
Ab-Neg: antibody-negative; ACA: anti-centromere antibody; ARA: anti-RNA polymerase antibody; ATA: anti-topoisomerase antibody; ELISA: enzyme-linked immunosorbent assay; IFN: interferon; IL: interleukin; SSc: systemic sclerosis; Th1: T-helper type 1; Th2: T-helper type 2; TNF: tumor necrosis factor.
The authors declare that they have no competing interests.
PG, FCA, FKT, MDM, JDR and SKA designed the project. PG, SA, MH, LD, MDM, JDR and SKA acquired the data. PG, FCA, SA, FKT, MH, LD and SKA analyzed the data. All authors read and approved the final manuscript.
The present study was supported by the Scleroderma Foundation New Investigator Award (to SKA), NIH/NIAMS-K08AR054404 (to SKA), the NIH/NIAMS Center of Research Translation in Scleroderma (P50AR054144) (to FCA), the NIH/NIAMS Scleroderma Family Registry and DNA Repository (N01-AR-0-2251) (to MDM), and the University of Texas Health Science Center at Houston Center for Clinical and Translational Sciences (Houston CTSA Program) (NIH/NCRR 3UL1RR024148) (to FCA and SKA).
|Fleischmajer R,Perlish JS,Reeves JR,Cellular infiltrates in scleroderma skinArthritis RheumYear: 19772097598410.1002/art.1780200410861067|
|Tan FK,Zhou X,Mayes MD,Gourh P,Guo X,Marcum C,Jin L,Arnett FC Jr,Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patientsRheumatology (Oxford)Year: 20064569470210.1093/rheumatology/kei24416418202|
|Mavalia C,Scaletti C,Romagnani P,Carossino AM,Pignone A,Emmi L,Pupilli C,Pizzolo G,Maggi E,Romagnani S,Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosisAm J PatholYear: 1997151175117589403725|
|Needleman BW,Wigley FM,Stair RW,Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with sclerodermaArthritis RheumYear: 199235677210.1002/art.17803501111731816|
|Molteni M,Della BS,Mascagni B,Bazzi S,Zulian C,Compasso S,Lessi M,Scorza R,Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenonClin Exp ImmunolYear: 199911616416810.1046/j.1365-2249.1999.00842.x10209521|
|Hasegawa M,Sato S,Fujimoto M,Ihn H,Kikuchi K,Takehara K,Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosisJ RheumatolYear: 1998253083139489824|
|Hasegawa M,Sato S,Ihn H,Takehara K,Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosisRheumatology (Oxford)Year: 19993861261710.1093/rheumatology/38.7.61210461473|
|Sato S,Hasegawa M,Takehara K,Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosisJ Dermatol SciYear: 20012714014610.1016/S0923-1811(01)00128-111532378|
|Hasegawa M,Fujimoto M,Kikuchi K,Takehara K,Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosisJ RheumatolYear: 1997246636659101498|
|Hasegawa M,Fujimoto M,Kikuchi K,Takehara K,Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosisJ RheumatolYear: 1997243283329034992|
|Sato S,Hanakawa H,Hasegawa M,Nagaoka T,Hamaguchi Y,Nishijima C,Komatsu K,Hirata A,Takehara K,Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosisJ RheumatolYear: 2000272838284211128673|
|Arnett FC,Reveille JD,Valdez BC,Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseasesArthritis RheumYear: 1997401487149210.1002/art.17804010039259430|
|Arnett FC,Reveille JD,Goldstein R,Pollard KM,Leaird K,Smith EA,LeRoy EC,Fritzler MJ,Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysisArthritis RheumYear: 1996391151116010.1002/art.17803907128670324|
|Reveille JD,Fischbach M,McNearney T,Friedman AW,Aguilar MB,Lisse J,Fritzler MJ,Ahn C,Arnett FC,Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinantsSemin Arthritis RheumYear: 20013033234610.1053/sarh.2001.2026811303306|
|Meyer OC,Fertig N,Lucas M,Somogyi N,Medsger TA Jr,Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosisJ RheumatolYear: 20073410410917117486|
|Wu SP,Leng L,Feng Z,Liu N,Zhao H,McDonald C,Lee A,Arnett FC,Gregersen PK,Mayes MD,Bucala R,Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of sclerodermaArthritis RheumYear: 2006543661366910.1002/art.2217917075815|
|Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria CommitteeArthritis RheumYear: 19802358159010.1002/art.17802305107378088|
|LeRoy EC,Black C,Fleischmajer R,Jablonska S,Krieg T,Medsger TA Jr,Rowell N,Wollheim F,Scleroderma (systemic sclerosis): classification, subsets and pathogenesisJ RheumatolYear: 1988152022053361530|
|Chowdhury F,Williams A,Johnson P,Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profilingJ Immunol MethodsYear: 2009340556410.1016/j.jim.2008.10.00218983846|
|Olivier J,Johnson WD,Marshall GD,The logarithmic transformation and the geometric mean in reporting experimental IgE results: what are they and when and why to use them?Ann Allergy Asthma ImmunolYear: 200810033333718450118|
|Bombardieri S,Medsger TA Jr,Silman AJ,Valentini G,The assessment of the patient with systemic sclerosis. IntroductionClin Exp RheumatolYear: 200321S2S412889213|
|Naka T,Nishimoto N,Kishimoto T,The paradigm of IL-6: from basic science to medicineArthritis ResYear: 20024Suppl 3S233S24210.1186/ar56512110143|
|Giacomelli R,Cipriani P,Lattanzio R,Di FM,Locanto M,Parzanese I,Passacantando A,Ciocci A,Tonietti G,Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the diseaseClin Exp ImmunolYear: 1997108424610.1046/j.1365-2249.1997.d01-991.x9097909|
|McGaha TL,Bona CA,Role of profibrogenic cytokines secreted by T cells in fibrotic processes in sclerodermaAutoimmun RevYear: 2002117418110.1016/S1568-9972(02)00027-712849012|
|Valentini G,Baroni A,Esposito K,Naclerio C,Buommino E,Farzati A,Cuomo G,Farzati B,Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activationJ Clin ImmunolYear: 20012121021710.1023/A:101102431352511403228|
|Giacomelli R,Cipriani P,Fulminis A,Barattelli G,Matucci-Cerinic M,D'Alo S,Cifone G,Tonietti G,Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarizationClin Exp ImmunolYear: 200112531031510.1046/j.1365-2249.2001.01603.x11529924|
|Cua DJ,Sherlock J,Chen Y,Murphy CA,Joyce B,Seymour B,Lucian L,To W,Kwan S,Churakova T,Zurawski S,Wiekowski M,Lira SA,Gorman D,Kastelein RA,Sedgwick JD,Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brainNatureYear: 200342174474810.1038/nature0135512610626|
|Bettelli E,Carrier Y,Gao W,Korn T,Strom TB,Oukka M,Weiner HL,Kuchroo VK,Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNatureYear: 200644123523810.1038/nature0475316648838|
|Bettelli E,Korn T,Kuchroo VK,Th17: the third member of the effector T cell trilogyCurr Opin ImmunolYear: 20071965265710.1016/j.coi.2007.07.02017766098|
|Murata M,Fujimoto M,Matsushita T,Hamaguchi Y,Hasegawa M,Takehara K,Komura K,Sato S,Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?J Dermatol SciYear: 20085024024210.1016/j.jdermsci.2008.01.00118329249|
|Komura K,Fujimoto M,Hasegawa M,Ogawa F,Hara T,Muroi E,Takehara K,Sato S,Increased serum interleukin 23 in patients with systemic sclerosisJ RheumatolYear: 20083512012510.3899/jrheum.08012018085738|
|Reveille JD,Fischbach M,McNearney T,Friedman AW,Aguilar MB,Lisse J,Fritzler MJ,Ahn C,Arnett FC,Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinantsSemin Arthritis RheumYear: 20013033234610.1053/sarh.2001.2026811303306|
Demographics and clinical data of the cohort
|Controls (n = 216)||Scleroderma patients (n = 444)|
|Age (years)||51 ± 14 years||53 ± 12.1|
|Male||117 (54%)||56 (13%)|
|Female||99 (46%)||388 (87%)|
|Disease duration (years)||6.9 ± 0.3|
|Systemic sclerosis-association autoantibodies|
|Anti-RNA polymerase III||109 (25%)|
Data presented as mean ± standard deviation or n (%).
Plasma cytokine levels of healthy controls and scleroderma patients
|Healthy controls (n = 216)||Scleroderma patients (n = 444)||P value|
|pg/ml||logn cytokine||pg/ml||logn cytokine||Unpaired t test||Adjusted for age and gender|
|TNFα||8.9 ± 0.5||1.90 ± 0.06||14.1 ± 0.7||2.27 ± 0.05||<0.0001||<0.0001|
|IL1β||7.0 ± 1.2||0.36 ± 0.11||5.8 ± 0.8||0.38 ± 0.07||NS||NS|
|IL-6||5.2 ± 0.8||0.55 ± 0.11||9.7 ± 1.2||1.24 ± 0.07||<0.0001||<0.0001|
|IL-8||77.7 ± 20.1||1.32 ± 0.15||84.3 ± 13.8||1.58 ± 0.11||NS||NS|
|IL-2||2.8 ± 0.7||0.05 ± 0.08||2.4 ± 0.4||0.02 ± 0.05||NS||NS|
|IFNγ||2.9 ± 0.5||- 0.17 ± 0.08||8.2 ± 4.6||- 0.06 ± 0.06||NS||0.05|
|IL-12p70||16.2 ± 4.3||0.66 ± 0.12||53.2 ± 12.8||0.71 ± 0.09||NS||NS|
|IL-4||5.1 ± 0.8||0.38 ± 0.11||5.4 ± 1.2||0.32 ± 0.07||NS||NS|
|IL-5||1.2 ± 0.2||- 0.27 ± 0.05||11.1 ± 5.1||- 0.14 ± 0.06||NS||NS|
|IL-13||24.6 ± 1.7||2.97 ± 0.06||51.5 ± 12.0||3.12 ± 0.05||0.05||NS|
|IL-10||18.5 ± 11.6||0.62 ± 0.10||30.6 ± 10.0||0.83 ± 0.08||NS||0.07|
|IL-17||1.9 ± 0.2||0.04 ± 0.08||1.2 ± 0.1||- 0.22 ± 0.04||0.0009||0.0005|
|IL-23||4.7 ± 1.1||0.46 ± 0.12||3.7 ± 0.5||0.18 ± 0.07||0.04||0.014|
Plasma cytokine levels are presented as both absolute levels (pg/ml) as well as natural log-transformed (logn cytokine) to normalize the data for analysis. Data presented as the mean ± standard error of the mean. P value determined either by unpaired t test or by logistic regression controlling for age and gender; NS, not significant with P > 0.05.
Plasma cytokine associations with clinical involvement of scleroderma
|Present||Absent||Unknown||Cytokine||Odds ratio||95% confidence interval||P value|
|Interstitial lung disease||120||196||128||IL-6||1.33||1.08 to 1.62||0.006|
|Pulmonary hypertension||58||255||131||IL-6||1.31||1.04 to 1.67||0.02|
|IL-13||1.42||1.04 to 1.94||0.03|
|SSc renal crisis||20||294||130||TNFα||2.22||1.11 to 4.45||0.02|
|Sjogren's syndrome||118||199||127||IL-8||0.89||0.81 to 0.99||0.03|
|IL-1β||0.75||0.63 to 0.88||0.0006|
|Primary biliary cirrhosis||5||309||140||IL-17||3.46||1.35 to 8.9||0.01|
Cytokine levels were normalized using logn transformation. Logistic regression was used to compare cytokine levels to control subjects for gender and age and odd ratios reflect each cytokine as a continuous variable.
Previous Document: In vitro effect of fluoride oral hygiene tablets on artificial caries lesion formation and remineral...
Next Document: Early over expression of messenger RNA for multiple genes, including insulin, in the Pancreatic Lymp...